{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:01:17Z","timestamp":1740171677731,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Berliner Krebsgesellschaft"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13402-018-0387-3","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T04:10:12Z","timestamp":1532491812000},"page":"505-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells"],"prefix":"10.1007","volume":"41","author":[{"given":"Carsten","family":"Pelz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"H\u00e4ckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geo","family":"Semini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schr\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem","family":"Bintig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Mrawietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Lucka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Shmanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Eickholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Hildmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4682","authenticated-orcid":false,"given":"Kerstin","family":"Danker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"387_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics. CA Cancer J. Clin. 61, 69\u201390 (2011)","journal-title":"CA Cancer J. Clin."},{"key":"387_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/bcr919","volume":"6","author":"NU Lin","year":"2004","unstructured":"N.U. Lin, E.P. Winer, New targets for therapy in breast cancer: Small molecules tyrosine kinase inhibitors. Breast Cancer Res. 6, 204\u2013210 (2004)","journal-title":"Breast Cancer Res."},{"key":"387_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9440(10)61180-7","volume":"167","author":"RJ Weil","year":"2005","unstructured":"R.J. Weil, D.C. Palmieri, J.L. Bronder, A.M. Stark, P.S. Steeg, Breast cancer metastasis to the central nervous system. Am. J. Pathol. 167, 913\u2013920 (2005)","journal-title":"Am. J. Pathol."},{"key":"387_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10555-012-9377-5","volume":"31","author":"NP Gunasinghe","year":"2012","unstructured":"N.P. Gunasinghe, A. Wells, E.W. Thompson, H.J. Hugo, Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 31, 469\u2013478 (2012)","journal-title":"Cancer Metastasis Rev."},{"key":"387_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13402-018-0376-6","volume":"41","author":"M Yousefi","year":"2018","unstructured":"M. Yousefi, R. Nosrati, A. Salmaninejad, S. Dehghani, A. Shahryari, A. Saberi, Organ-specific metastasis of breast cancer: Molecular and cellular mechanisms underlying lung metastasis. Cell. Oncol. 41, 123\u2013140 (2018)","journal-title":"Cell. Oncol."},{"key":"387_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10495-011-0592-2","volume":"16","author":"C Haefen von","year":"2011","unstructured":"C. von Haefen, J. Wendt, .G Semini, M. Sifringer, C. Belka, S. Radetzki, W. Reutter, P.T. Daniel, K. Danker, Synthetic glycosidated phospholipids induce apoptosis through activation of FADD, caspase-8 and the mitochondrial death pathway. Apoptosis 16, 636\u2013651 (2011)","journal-title":"Apoptosis"},{"key":"387_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.bcp.2011.02.002","volume":"15","author":"G Semini","year":"2011","unstructured":"G. Semini, A. Hildmann, H.U. Reissig, W. Reutter, K. Danker, The novel synthetic ether lipid inositol-C2-PAF inhibits phosphorylation of the tyrosine kinases Src and FAK independent of integrin activation in transformed skin cells. Biochem. Pharmacol. 15, 985\u2013995 (2011a)","journal-title":"Biochem. Pharmacol."},{"key":"387_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cbic.200500336","volume":"7","author":"A Fischer","year":"2006","unstructured":"A. Fischer, D. M\u00fcller, M. Zimmermann-Kordmann, B. Kleuser, M. Mickeleit, S. Laabs, W. L\u00f6we, F. Cantagrel, W. Reutter, K. Danker, The ether lipid inositol-C2-PAF is a potent inhibitor of cell proliferation in HaCaT cells. Chembiochem 7, 441\u2013449 (2006)","journal-title":"Chembiochem"},{"key":"387_CR9","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/jid.2014.170","volume":"134","author":"S Forkel","year":"2014","unstructured":"S. Forkel, M. Sch\u00f6n, A. Hildmann, A. Cla\u00dfen, S.M. John, K. Danker, M.P. Sch\u00f6n, Inositoylated platelet activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models. J. Invest. Dermatol. 134, 2510\u20132520 (2014)","journal-title":"J. Invest. Dermatol."},{"key":"387_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/FPC.0b013e32834549b9","volume":"21","author":"G Semini","year":"2011","unstructured":"G. Semini, A. Klein, K. Danker, Impact of alkylphospholipids on the gene expression profile of HaCaT cells. Pharmacogenet. Genomics 21, 375\u2013387 (2011b)","journal-title":"Pharmacogenet. Genomics"},{"key":"387_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bcp.2013.11.012","volume":"87","author":"G Semini","year":"2014","unstructured":"G. Semini, A. Hildmann, A. Klein, L. Lucka, M. Sch\u00f6n, M.P. Sch\u00f6n, V. Shmanai, K. Danker, Inositol-C2-PAF down-regulates components of the antigen presentation machinery in a 2D-model of epidermal inflammation. Biochem. Pharmacol. 87, 477\u2013488 (2014)","journal-title":"Biochem. Pharmacol."},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjc.6603078","volume":"94","author":"DR Emlet","year":"2006","unstructured":"D.R. Emlet, R. Schwartz, K.A. Brown, A.A. Pollice, C.A. Smith, S.E. Shackney, HER2 expression as a potential marker for response to therapy targeted to the EGFR. British J. Cancer 94, 1144\u20131153 (2006)","journal-title":"British J. Cancer"},{"key":"387_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11010-013-1643-5","volume":"379","author":"B Gottschalk","year":"2013","unstructured":"B. Gottschalk, A. Klein, Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype. Mol. Cell. Biochem. 379, 213\u2013227 (2013)","journal-title":"Mol. Cell. Biochem."},{"key":"387_CR14","doi-asserted-by":"publisher","first-page":"10239","DOI":"10.1074\/jbc.M115.700138","volume":"291","author":"S Schr\u00f6tter","year":"2016","unstructured":"S. Schr\u00f6tter, G. Leondaritis, B.J. Eickholt, Capillary isoelectric focusing of Akt isoforms identifies highly dynamic phosphorylation in neuronal cells and brain tissue. J. Biol. Chem. 291, 10239\u201310251 (2016)","journal-title":"J. Biol. Chem."},{"key":"387_CR15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/modpathol.3800424","volume":"18","author":"AL Lark","year":"2005","unstructured":"A.L. Lark, C.A. Livasy, L. Dressler, D.T. Moore, R.C. Millikan, J. Geradts, M. Iacocca, D. Cowan, D. Little, R.J. Craven, W. Cance, High focal adhesion kinase expression in invasive breast carcinoma is associated with an aggressive phenotype. Mod. Pathol. 18, 1289\u20131294 (2005)","journal-title":"Mod. Pathol."},{"key":"387_CR16","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","volume":"16","author":"EL Mayer","year":"2010","unstructured":"E.L. Mayer, I.E. Krop, Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin. Cancer. Res. 16, 3526\u20133532 (2010)","journal-title":"Clin. Cancer. Res."},{"key":"387_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/156800908784293659","volume":"8","author":"A Carnero","year":"2008","unstructured":"A. Carnero, C. Blanco-Aparicio, O. Renner, W. Link, J.F. Leal, The PTEN\/PI3K\/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 8, 187\u2013198 (2008)","journal-title":"Curr. Cancer Drug Targets"},{"key":"387_CR18","doi-asserted-by":"publisher","first-page":"e103534","DOI":"10.1371\/journal.pone.0103534","volume":"9","author":"S Sarkissyan","year":"2014","unstructured":"S. Sarkissyan, M. Sarkissyan, Y. Wu, J. Cardenas, H.P. Koeffler, J.V. Vadgama, IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One 9, e103534 (2014)","journal-title":"PLoS One"},{"key":"387_CR19","first-page":"1181","volume":"32","author":"TT Rajah","year":"2012","unstructured":"T.T. Rajah, K.J. Peine, N. Du, C.A. Serret, N.R. Drews, Physiological concentrations of genistein and 17\u03b2-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX\/BCL-2 and reducing pERK1\/2. Anticancer Res. 32, 1181\u20131191 (2012)","journal-title":"Anticancer Res."},{"key":"387_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1478-811X-9-10","volume":"9","author":"LA Walsh","year":"2011","unstructured":"L.A. Walsh, S. Damjanovski, IGF-1 increases invasive potential of MCF7 breast cancer cells and induces activation of latent TGF-\u03b21 resulting in epithelial to mesenchymal transition. Cell Commun. Signal. 9, 10\u201321 (2011)","journal-title":"Cell Commun. Signal."},{"key":"387_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","volume":"12","author":"PT Bhaskar","year":"2007","unstructured":"P.T. Bhaskar, N. Hay, The two TORCs and Akt. Dev. Cell 12, 487\u2013502 (2007)","journal-title":"Dev. Cell"},{"key":"387_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bbalip.2012.10.008","volume":"1831","author":"WJ Blitterswijk van","year":"2013","unstructured":"W.J. van Blitterswijk, M. Verheij, Anticancer mechanisms and clinical application of alkylphospholipids. Biochim. Biophys. Acta 1831, 663\u2013674 (2013)","journal-title":"Biochim. Biophys. Acta"},{"key":"387_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1871520614666140309222259","volume":"14","author":"C Gajate","year":"2014","unstructured":"C. Gajate, F. Mollinedo, Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine. Anti Cancer Agents Med. Chem. 14, 509\u2013527 (2014)","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"387_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.phrs.2015.02.007","volume":"95-96","author":"S Melo-Lima","year":"2015","unstructured":"S. Melo-Lima, M.C. Lopes, F. Mollinedo, ERK1\/2 acts as a switch between necrotic and apoptotic cell death in ether phospholipid edelfosine-treated glioblastoma cells. Pharmacol. Res. 95-96, 2\u201311 (2015)","journal-title":"Pharmacol. Res."},{"key":"387_CR25","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1038\/onc.2010.131","volume":"29","author":"F Mollinedo","year":"2010","unstructured":"F. Mollinedo, J. de la Iglesia-Vicente, C. Gajate, A. Estella-Hermoso de Mendoza, J.A. Villa-Pulgarin, M.A. Campanero, M.J. Blanco-Prieto, Lipid raft-targeted therapy in multiple myeloma. Oncogene 29, 3748\u20133757 (2010)","journal-title":"Oncogene"},{"key":"387_CR26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1189\/jlb.2MR0215-055R","volume":"98","author":"C Gajate","year":"2015","unstructured":"C. Gajate, F. Mollinedo, Lipid raft-mediated Fas\/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications. J. Leukoc. Biol. 98, 739\u2013759 (2015)","journal-title":"J. Leukoc. Biol."},{"key":"387_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.2174\/1871520614666140309224145","volume":"14","author":"Verheij","year":"2014","unstructured":"Verheij, W.H. Moolenaar, W.J. van Blitterswijk, Combining anti-tumor alkyl-phospholipid analogs and radiotherapy: Rationale and clinical outlook. Anti Cancer Agents Med. Chem. 14, 618\u2013628 (2014)","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"387_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1476-5381.2009.00626.x","volume":"160","author":"K Danker","year":"2010","unstructured":"K. Danker, W. Reutter, G. Semini, Glycosidated phospholipids: Uncoupling of signalling pathways at the plasma membrane. Br. J. Pharmacol. 160, 36\u201347 (2010)","journal-title":"Br. J. Pharmacol."},{"key":"387_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.4149\/neo_2012_032","volume":"59","author":"X Lin","year":"2012","unstructured":"X. Lin, X. Zhang, Q. Wang, J. Li, P. Zhang, M. Zhao, X. Li, Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K\/Akt\/NF-\u03baB signaling pathway in a human breast cancer cell line. Neoplasma 59, 248\u2013256 (2012)","journal-title":"Neoplasma"},{"key":"387_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ejmech.2011.11.018","volume":"247","author":"MM Alam","year":"2012","unstructured":"M.M. Alam, E.H. Joh, Y. Kim, Y.I. Oh, J. Hong, B. Kim, D.H. Kim, Y.S. Lee, Synthesis and biological evaluation of cyclopentane-linked alkyl phosphocholines as potential anticancer agents that act by inhibiting Akt phosphorylation. Eur. J. Med. Chem. 247, 485\u2013492 (2012)","journal-title":"Eur. J. Med. Chem."},{"key":"387_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ijpharm.2013.04.068","volume":"454","author":"M\u00c1 Aznar","year":"2013","unstructured":"M.\u00c1. Aznar, B. Lasa-Sarac\u00edbar, A. Estella-Hermoso de Mendoza, M.J. Blanco-Prieto, Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int. J. Pharm. 454, 720\u2013726 (2013)","journal-title":"Int. J. Pharm."},{"key":"387_CR32","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00280-011-1658-0","volume":"68","author":"RG Bagley","year":"2011","unstructured":"R.G. Bagley, L. Kurtzberg, C. Rouleau, M. Yao, B.A. Teicher, Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells. Cancer Chemother. Pharmacol. 68, 1537\u20131546 (2011)","journal-title":"Cancer Chemother. Pharmacol."},{"key":"387_CR33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1476-5381.2010.01044.x","volume":"162","author":"M Potier","year":"2011","unstructured":"M. Potier, A. Chantome, V. Joulin, A. Girault, S. Roger, P. Besson, M.L. Jourdan, J.Y. LeGuennec, P. Bougnoux, C. Vandier, The SK3\/KCa2.3. Potassium channel is a new cellular target for edelfosine. Br. J. Pharmacol. 162, 464\u2013479 (2011)","journal-title":"Br. J. Pharmacol."},{"key":"387_CR34","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-12-4572","volume":"73","author":"A Chant\u00f4me","year":"2013","unstructured":"A. Chant\u00f4me, M. Potier-Cartereau, L. Clarysse, G. Fromont, S. Marionneau-Lambot, M. Gu\u00e9guinou, J.C. Pag\u00e8s, C. Collin, T. Oullier, A. Girault, F. Arbion, J.P. Haelters, P.A. Jaffr\u00e8s, M. Pinault, P. Besson, V. Joulin, P. Bougnoux, C. Vandier, Pivotal role of the lipid raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 73, 4852\u20134861 (2013)","journal-title":"Cancer Res."},{"key":"387_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2016.06.003","volume":"165","author":"PA Jaffr\u00e8s","year":"2016","unstructured":"P.A. Jaffr\u00e8s, C. Gajate, A.M. Bouchet, H. Couthon-Gourv\u00e8s, A. Chant\u00f4me, M. Potier-Cartereau, P. Besson, P. Bougnoux, F. Mollinedo, C. Vandier, Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy. Pharmacol. Ther. 165, 114\u2013131 (2016)","journal-title":"Pharmacol. Ther."},{"key":"387_CR36","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1021\/jm050558n","volume":"48","author":"T Bartolm\u00e4s","year":"2005","unstructured":"T. Bartolm\u00e4s, T. Heyn, M. Mickeleit, A. Fischer, W. Reutter, K. Danker, Glucosamine-glycerophospholipids that activate cell-matrix adhesion and migration. J. Med. Chem. 48, 6750\u20136755 (2005)","journal-title":"J. Med. Chem."},{"key":"387_CR37","first-page":"1285","volume":"11","author":"DC Schallier","year":"1991","unstructured":"D.C. Schallier, E.A. Bruyneel, G.A. Storme, P. Hilgard, M.M. Mareel, Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res. 11, 1285\u20131292 (1991)","journal-title":"Anticancer Res."},{"key":"387_CR38","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0022-5347(17)32485-0","volume":"152","author":"JW Slaton","year":"1994","unstructured":"J.W. Slaton, J.A. Hampton, S.H. Selman, Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J. Urol. 152, 1594\u20131598 (1994)","journal-title":"J. Urol."},{"key":"387_CR39","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2174\/156800911798073069","volume":"11","author":"A Girault","year":"2011","unstructured":"A. Girault, J.P. Haelters, M. Potier-Cartereau, A. Chant\u00f4me, M. Pinault, S. Marionneau-Lambot, T. Oullier, G. Simon, H. Couthon-Gourv\u00e8s, P.A. Jaffr\u00e8s, B. Corbel, P. Bougnoux, V. Joulin, C. Vandier, New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Curr. Cancer Drug Targets 11, 1111\u20131125 (2011)","journal-title":"Curr. Cancer Drug Targets"},{"key":"387_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF01753687","volume":"7","author":"EA Bruyneel","year":"1989","unstructured":"E.A. Bruyneel, J.G. Bolscher, L.A. Smets, M. De Mets, M.M. Mareel, Restored invasion of mouse MO4 cells into chick heart in vitro through mutual conditioning at reduced temperature. Clin. Exp. Metastasis 7, 361\u2013371 (1989)","journal-title":"Clin. Exp. Metastasis"},{"key":"387_CR41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ijc.1216","volume":"92","author":"WF Steelant","year":"2001","unstructured":"W.F. Steelant, J.L. Goeman, J. Philipp\u00e9, L.C. Oomen, J. Hilkens, M.A. Krzewinski-Recchi, G. Huet, J. Van der Eycken, P. Delannoy, E.A. Bruyneel, M.M. Mareel, Alkyl-lysophospholipid 1-O-octadecyl-2-O-methyl-glycerophosphocholine induces invasion through episialin-mediated neutralization of E-cadherin in human mammary MCF-7 cells in vitro. Int. J. Cancer 92, 527\u2013536 (2001)","journal-title":"Int. J. Cancer"},{"key":"387_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1042\/BJ20060944","volume":"401","author":"S Slambrouck van","year":"2007","unstructured":"S. van Slambrouck, W.F. Steelant, Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells. Biochem. J. 401, 689\u2013699 (2007)","journal-title":"Biochem. J."},{"key":"387_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10637-005-1436-0","volume":"23","author":"SR Vink","year":"2005","unstructured":"S.R. Vink, J.H. Schellens, W.J. van Blitterswijk, M. Verheij, Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Investig. New Drugs 23, 279\u2013286 (2005)","journal-title":"Investig. New Drugs"},{"key":"387_CR44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jconrel.2011.07.030","volume":"156","author":"A Estella-Hermoso de Mendoza","year":"2011","unstructured":"A. Estella-Hermoso de Mendoza, V. Pr\u00e9at, F. Mollinedo, M.J. Blanco-Prieto, In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156, 421\u2013426 (2011)","journal-title":"J. Control. Release"},{"key":"387_CR45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00001813-200302000-00011","volume":"14","author":"GA Ruiter","year":"2003","unstructured":"G.A. Ruiter, S.F. Zerp, H. Bartelink, W.J. van Blitterswijk, M. Verheij, Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt\/PKB survival pathway. Anti-Cancer Drugs 14, 167\u2013173 (2003)","journal-title":"Anti-Cancer Drugs"},{"key":"387_CR46","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.2174\/092986711796011292","volume":"18","author":"EJ Meuillet","year":"2011","unstructured":"E.J. Meuillet, Novel inhibitors of AKT: Assessment of a different approach targeting the pleckstrin homology domain. Curr. Med. Chem. 18, 2727\u20132742 (2011)","journal-title":"Curr. Med. Chem."},{"key":"387_CR47","first-page":"241","volume":"347","author":"ME Feldman","year":"2010","unstructured":"M.E. Feldman, K.M. Shokat, New inhibitors of the PI3K-Akt-mTOR pathway: Insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs). Curr. Top. Microbiol. Immunol. 347, 241\u2013262 (2010)","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"387_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1091\/mbc.8.2.287","volume":"8","author":"L Connell-Crowley","year":"1997","unstructured":"L. Connell-Crowley, J.W. Harper, D.W. Goodrich, Cyclin D1\/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8, 287\u2013301 (1997)","journal-title":"Mol. Biol. Cell"},{"key":"387_CR49","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.bbalip.2016.09.001","volume":"1861","author":"CS Gradziel","year":"2016","unstructured":"C.S. Gradziel, P.A. Jordan, D. Jewel, F.J. Dufort, S.J. Miller, T.C. Chiles, M.F. Roberts, D-3-deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway. Biochim. Biophys. Acta. 1861, 1808\u20131815 (2016)","journal-title":"Biochim. Biophys. Acta."},{"issue":"44","key":"387_CR50","doi-asserted-by":"publisher","first-page":"16153","DOI":"10.1073\/pnas.0607973103","volume":"103","author":"R. A. O'Neill","year":"2006","unstructured":"R.A. O\u2019Neill, A. Bhamidipati, X. Bi, D. Deb-Basu, L. Cahill, J. Ferrante, E. Gentalen, M. Glazer, J. Gossett, K. Hacker, C. Kirby, J. Knittle, R. Loder, C. Mastroieni, M. Maclaren, T. Mills, U. Nguyen, N. Parker, A. Rice, D. Roach, D. Suich, D. Voehringer, K. Voss, J. Yang, T. Yang, P.B. Vander Horn. Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc. Natl. Acad. Sci. USA. 103, 16153\u201316158 (2006)","journal-title":"Proceedings of the National Academy of Sciences"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13402-018-0387-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-018-0387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-018-0387-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T19:10:58Z","timestamp":1563995458000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13402-018-0387-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s13402-018-0387-3","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"type":"print","value":"2211-3428"},{"type":"electronic","value":"2211-3436"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"7 June 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human paricipants and\/or animals"}},{"value":"For this type of study informed consent is not required","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}